Humacyte, Inc. (HUMA)
Total Valuation
Humacyte has a market cap or net worth of $485.15 million. The enterprise value is $330.01 million.
| Market Cap | 485.15M |
| Enterprise Value | 330.01M |
Important Dates
The latest earnings date was Friday, May 13, 2022, before market open.
| Last Earnings Date | May 13, 2022 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 103.01 million shares outstanding. The number of shares has increased by 1,653.35% in one year.
| Shares Outstanding | 103.01M |
| Shares Change (YoY) | +1,653.35% |
| Shares Change (QoQ) | +157.70% |
| Owned by Insiders (%) | 49.75% |
| Owned by Institutions (%) | 11.61% |
| Float | 50.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 361.78 |
| PB Ratio | 4.67 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 246.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.45, with a Debt / Equity ratio of 0.49.
| Current Ratio | 19.45 |
| Quick Ratio | 19.18 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -11.00% |
| Return on Capital (ROIC) | -21.20% |
| Revenue Per Employee | $9,248 |
| Profits Per Employee | -$179,366 |
| Employee Count | 145 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.90% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -50.90% |
| 50-Day Moving Average | 6.48 |
| 200-Day Moving Average | 7.18 |
| Average Volume (30 Days) | 376,865 |
Short Selling Information
The latest short interest is 5.89 million, so 5.71% of the outstanding shares have been sold short.
| Short Interest | 5.89M |
| Short % of Shares Out | 5.71% |
| Short % of Float | 11.55% |
| Short Ratio (days to cover) | 18.25 |
Income Statement
In the last 12 months, Humacyte had revenue of $1.34 million and -26.01 million in losses. Earnings per share was -$0.41.
| Revenue | 1.34M |
| Gross Profit | 1.34M |
| Operating Income | -83.20M |
| Net Income | -26.01M |
| EBITDA | -12.51M |
| EBIT | -20.76M |
| Earnings Per Share (EPS) | -$0.41 |
Balance Sheet
The company has $206.22 million in cash and $51.08 million in debt, giving a net cash position of $155.14 million or $1.51 per share.
| Cash & Cash Equivalents | 206.22M |
| Total Debt | 51.08M |
| Net Cash | 155.14M |
| Net Cash Per Share | $1.51 |
| Book Value | 103.89M |
| Book Value Per Share | 1.01 |
| Working Capital | 198.53M |
Cash Flow
In the last 12 months, operating cash flow was -$85.44 million and capital expenditures -$213,000, giving a free cash flow of -$85.66 million.
| Operating Cash Flow | -85.44M |
| Capital Expenditures | -213,000 |
| Free Cash Flow | -85.66M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -6,204.47% and -1,939.45%.
| Gross Margin | 100.00% |
| Operating Margin | -6,204.47% |
| Pretax Margin | n/a |
| Profit Margin | -1,939.45% |
| EBITDA Margin | -932.66% |
| EBIT Margin | -1,548.17% |
| FCF Margin | -6,387.55% |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -5.36% |
| FCF Yield | -17.66% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,653.35% |
| Shareholder Yield | -1,653.35% |
Analyst Forecast
The average price target for Humacyte is $14.96, which is 217.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.96 |
| Price Target Difference | 217.62% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |